2John LD. Quality of life in patients receiving radiation therapy for non-small cell lung cancer.Oncol-Nurs-Forum,2001,28(5): 807-813.
3Bergman B, Aronson NK,Cull A,et al. The EORTC QLQ-LC13:a modular supplement to the EORTC core quality of life (QLQ-C30)foruse in lung cancer clinical trials.Eur J Cancer,1994,30A:635-642.
4Langendijk JA. Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys,2000, 47(1): 149-155.
5Johnson JR,Temple R. Food and drug administration requirements for approval of new anti-cancer drugs[J]. Cancer Treat Rep, 1985,69(10) : 1155-1157.
6Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30:a quality of life instrument for use in international clinical trials in oncology [J]. J Natl Cancer Inst, 1993,85 (5) : 365-376.
7Aaronson NK, Cull A, Kaasa S, et al. The EORTC modular approach to quality of life assessment in ontology [J]. Int J Ment Health, 1994,23 (4):75-96.
4Piccoli F, Ory G, Hadengue A et al. Effect of intravenous esomeprazole 40mg and pantoPrazole 40mg on intragastric pH in healthy subjects. A prospective open randomized twoway erussover comparative study [J].. Arzneimittelfoesehung, 2007, 57 (10): 654-58.
